The University of Rochester received a $581,493 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to determine how the protein kinase D3 (PKD3) regulates endothelial-mesenchymal transition (EndMT) and heart valve development, function, and pathological changes. The goal is to better understand the molecular mechanisms underlying valvular heart disease (VHD) in order to develop new therapeutic strategies. The award commences on August 1, 2024 and is scheduled for completion by July 31, 2025. This research aims to have a significant impact on understanding EndMT and cardiac valve biology, providing valuable insights into the causes of VHD.
Generated 3/4/25, 6:35 AM